雄激素削减疗法（ADT）自上个世纪以来一直是治疗新诊断的转移性前列腺癌患者的治疗基石。根据过去十年里标志性试验的结果，ADT与化疗或新型激素药物的联合疗法已经成为这些患者的新的治疗标准。这种治疗范式的转变已经反映在主要专业协会指南建议的更新中。然而，来自世界各地的真实数据突出了联合疗法的使用不足，尽管有基于证据的建议。证据和实践之间的差距令人担忧，尤其是随着三联药物方案（ADT、多西他赛和新型激素药物）进一步治疗强化具有生存益处的新证据的出现。因此，迫切需要引起关注，并号召泌尿肿瘤学界采取行动，为这些患者提供基于证据的护理。© 2022. Springer Nature Limited.

Androgen deprivation therapy (ADT) alone has been the cornerstone of treatment for patients with newly diagnosed metastatic prostate cancer for the past century. Based on results from landmark trials in the past decade, combination approaches of ADT with chemotherapy or novel hormonal agents have established a new standard of care for these patients. This paradigm shift in treatment has been reflected in the updates to guideline recommendations of major professional associations. However, real-world data from around the world have highlighted the dismal adoption of combination therapy, despite evidence-based recommendations. The disparity between evidence and practice is concerning, especially with emerging evidence of survival benefit with further treatment intensification using triplet combinations (ADT, docetaxel and novel hormonal agents). Thus, a pressing need to raise awareness and call the uro-oncology community to action exists to deliver evidence-based care for these patients.© 2022. Springer Nature Limited.